Of interest, our understanding about the role of the VHL/HIF pathway could change the current standard of care in RCC, based on the synergic effect of anti-angiogenic agents and immune checkpoint inhibitors on immunomodulation [18]. Here, VHL is linked to renal cell carcinoma.